We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens and Nephromics to Develop Preeclampsia Diagnostic Assays

By LabMedica International staff writers
Posted on 07 Sep 2011
Siemens Healthcare Diagnostics (Tarrytown, NY, USA) has entered into a licensing agreement with Nephromics, LLC (Chestnut Hill, MA, USA) to develop two assays to be used as an aid in the diagnosis of preeclampsia.

The assays being developed are for the detection of two biomarkers, soluble fms-like tyrosine-kinase-1 (SFLT-1) and placental growth factor (PLGF). Clinical studies have shown that these two assays, when used in conjunction with each other, are better predictors of preeclampsia than either marker alone. Under the terms of the agreement, Siemens Healthcare Diagnostics will obtain rights for the development of the SFLT-1 and PLFG assays.

The addition of these assays will complement Siemens’ existing portfolio of integrated OB/GYN diagnostic solutions, which include both ultrasound imaging and reproductive endocrinology laboratory testing. Healthcare professionals are looking to the integration of in vitro and in vivo diagnostics in the practice of maternal/fetal diagnostic medicine.

Preeclampsia affects at least 5% to 8% of all pregnancies and is a leading cause of  maternal and fetal mortality. Currently, the standard methodologies for prescreening pregnant women at risk for preeclampsia are routine blood pressure monitoring and testing for protein in the urine during prenatal visits. However, with these methods, preeclampsia is often diagnosed at an advanced stage when there are limited treatment options.

“Given the prevalence and associated mortality with preeclampsia, clinicians need better diagnostic tools to identify the condition before it becomes advanced,” said Dave Hickey, CEO, Chemistry, Immunoassay, Automation, and Diagnostics IT Business Unit, Siemens Healthcare Diagnostics. “The development of assays designed to detect preeclampsia earlier is an evolving area of diagnostic medicine, and we are excited to enter into the agreement with Nephromics to offer these diagnostic solutions to our customers, clinicians, and patients.”

Related Links:

Siemens Healthcare Diagnostics







Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Pan-Cancer Panel
TruSight Oncology 500

Latest Industry News

Quanterix Completes Acquisition of Akoya Biosciences
07 Sep 2011  |   Industry

Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
07 Sep 2011  |   Industry

AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
07 Sep 2011  |   Industry



PURITAN MEDICAL